Singapore Clinical Trial: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Effica... Read More

Singapore Clinical Trial: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More

Singapore Clinical Trial: A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bev... Read More

Singapore Clinical Trial: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More

Singapore Clinical Trial: A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherap... Read More

Singapore Clinical Trial: A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LY4226695 in healthy participants.

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharma... Read More

Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More

Singapore Clinical Trial: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and E... Read More

Singapore Clinical Trial: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More

Singapore Clinical Trial: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More

• ««
• «
• 3358
• 3359
• 3360
• 3361
• 3362
• 3363
• 3364
• 3365
• 3366
• 3367
• »
• »»